Antivirt® {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses and abnormal (infected/tumor) cells are negatively charged but normal cells are neutral. Molecules of Aluminum-magnesium silicate (AMS), a WHO- approved medicine, consist of Nanoparticles that have both negatively and positively charged ends. Ultra-small size (0.96 nm thick) of the Nanoparticles, allows them access to cells in all organs. Nigeria does not have natural AMS-deposits but she has Aluminum silicate and Magnesium silicate, abundantly. These solid minerals which are WHO-approved medicines too were used to formulate an AMS-brand, named, Medicinal synthetic AMS (MSAMS, VITUMED®, Antivirt®). Dextrose monohydrate (simple sugar) is incorporated in each MSAMS-formulation to convey the electrically charged Nanoparticles across mucous membranes (active-transportation) into blood for circulation to all organs. The Antivirt® has proved effective against all viral and abnormal-cell diseases so far tested including COVID-19.

Electrostatic Mopping of Viruses with Medicinal Synthetic Aluminum-Magnesium Silicate {Al₄(SiO₄)₃+ 3Mg₂SiO₄→ 2Al₂Mg₃(SiO₄)₃}, for Quick Cure of COVID-19: A Better Control Measure

COVID-19 virus has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. Nanoparticles (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication;mopping extra-cellular viruses/abnormal cells;clearing secondary infections;enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for Medicinal synthetic AMS {MSAMS: Al4 (SiO4)3 + 3Mg2SiO4 → 2Al2Mg3 (SiO4)3}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its Nanoparticles into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).

Reducing Side Effects of Chloroquine with <i>Medicinal Synthetic Aluminum-Magnesium Silicate</i>&reg;[Msams: Al₄(SiO₄)₃+ 3Mg₂SiO₄→2Al₂Mg₃(SiO₄)₃] before Assessing Its Anti-Covid-19 Efficacy

To reduce Chloroquine’s (CQ) side effects, so that increasing its duration for anti-Covid-19 trials could be safe, the drug was potentiated by stabilizing it with Medicinal synthetic Aluminum-magnesium silicate (MSAMS). CQ-treatment for five Plasmodium berghie-infected mice-groups were: 7 mg/kg (normal dose);7 mg/kg (CQ-MSAMS);7 mg/kg (CQ-MSAMS + B-vitamins), 5.25 mg/kg (CQ-MSAMS + B-vitamins) and the control. Means of parasitaemia, 42.00 ± 15.74 of the normal-dose group, 37.22 ± 11.88 of the 7 mg/kg (CQ-MSAMS) group and 33.57 ± 12.62 of the 7 mg/kg (CQ-MSAMS + B-vitamins) group showed no significant (P ≥ 0.05) reduction from 52.50 ± 11.99 of the control, but the 5.25 mg/kg (CQ-MSAMS + B-vitamins) dose, cleared (P ≤ 0.01) the parasiteamia (00.00 ± 00.00), showing that MSAMS-potentiated Chloroquine, has best efficacy at 75% of the recommended dose. Fever and anemia were absent at that 5.25 mg/kg, suggesting that lower doses of CQ have reduced side effects.